IPSC Revenue Breakdown
IPSC Revenue Breakdown summary
Century Therapeutics, Inc. (IPSC). Quarter ended 2025-12-31 · 10-Q · every retained filed quarter remains available.
- 2025-12-31: Others Not split by product in the filing$109.16M100.00%; Total revenue $109.16M.
- 2024-12-31: Others Not split by product in the filing$6.59M100.00%; Total revenue $6.59M.
- 2023-12-31: Others Not split by product in the filing$2.23M100.00%; Total revenue $2.23M.
- 2022-12-31: Others Not split by product in the filing$5.20M100.00%; Total revenue $5.20M.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $109.16M 100.00% | $109.16M |
| 2024-12-31 | Not split by product in the filing $6.59M 100.00% | $6.59M |
| 2023-12-31 | Not split by product in the filing $2.23M 100.00% | $2.23M |
| 2022-12-31 | Not split by product in the filing $5.20M 100.00% | $5.20M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product $0.00 | $0.00 |
| 2025-09-30 | Not split by product $0.00 | $0.00 |
| 2025-06-30 | Not split by product $0.00 | $0.00 |
| 2025-03-31 | Not split by product $109.16M 100.00% | $109.16M |
| 2024-12-31 | Not split by product $4.17M 100.00% | $4.17M |
| 2024-09-30 | Not split by product $791.00K 100.00% | $791.00K |
| 2024-06-30 | Not split by product $771.00K 100.00% | $771.00K |
| 2024-03-31 | Not split by product $855.00K 100.00% | $855.00K |
| 2023-12-31 | Not split by product $268.00K 100.00% | $268.00K |
| 2023-09-30 | Not split by product $148.00K 100.00% | $148.00K |
| 2023-06-30 | Not split by product $99.00K 100.00% | $99.00K |
| 2023-03-31 | Not split by product $1.72M 100.00% | $1.72M |
| 2022-12-31 | Not split by product $521.00K 100.00% | $521.00K |
| 2022-09-30 | Not split by product $2.22M 100.00% | $2.22M |
| 2022-06-30 | Not split by product $1.40M 100.00% | $1.40M |
| 2022-03-31 | Not split by product $1.06M 100.00% | $1.06M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |